Costs of medical care among augmentation therapy users and non-users with alpha-1 antitrypsin deficiency in the United States

Jan Sieluk, Joseph Levy, Robert A. Sandhaus, Henry Silverman, Kristen E. Holm, C. Daniel Mullins

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This study is the first to utilize a large claims database to estimate medical costs of patients with alpha-1 antitrypsin deficiency (AATD) in the United States. Methods: Adult AATD patients were identified from the OptumLabs™ Data Warehouse. Insurer and patient out-of-pocket costs were categorized into the following cost buckets, stratified by augmentation therapy use: physician visits (PV), emergency department visits (ED), inpatient stays (IP), augmentation therapy (AUG), other prescription drug costs (RX), and other costs (OTH). Costs were weighted and adjusted to 2017 U.S. dollars using the medical care component of the consumer price index. Results: The study cohort consisted of 9117 AATD patients followed for 53,872 person years observed between 1993 and 2015. The annual costs among AATD patients totaled $127,537 among augmentation therapy users and $15,874 among non-users. The major drivers of annual costs to the insurer among the 7975 patients not on augmentation therapy were: PV: $5352 (37.7%) and IP: $4506 (31.8%). Among the 1142 augmentation users, major annual cost drivers to the insurer were PV: $15,064 (12.3%) and AUG: $82,002 (66.7%). Annual patient out-of-pocket costs were $4601 (AUG: $2084 [45.3%]; RX: $940 [20.4%]) and $1689 (PV: $727 [43.0%]; RX: $589 [34.9%]) among augmentation therapy users and non-users, respectively. Averaged across the entire cohort, the average annual costs per AATD patient were $22,975, paid by insurers ($21,100) and patients ($1875). Conclusions: Annual medical costs among patients with AATD are $127,537 and $15,874 among augmentation therapy users and non-users, respectively, with 75.3% of the cost difference attributable to AUG.

Original languageEnglish (US)
Pages (from-to)6-16
Number of pages11
JournalChronic Obstructive Pulmonary Diseases
Volume6
Issue number1
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Alpha-1 antitrypsin deficiency
  • Augmentation therapy
  • Chronic obstructive pulmonary disease
  • Medical costs
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Costs of medical care among augmentation therapy users and non-users with alpha-1 antitrypsin deficiency in the United States'. Together they form a unique fingerprint.

Cite this